Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation

Lewis, 1929, Observations upon the vascular mechanism in acrocyanosis, Heart, 15, 229

Moncada, 1979, Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2 and prostacyclin, Pharmacol Rev, 30, 293

Coughlin, 1980, Platelet-dependent stimulation of prostacyclin synthesis by platelet-derived growth factor, Nature, 288, 600, 10.1038/288600a0

Coughlin, 1981, Serotonin recepted-mediated stimulation of smooth muscle cell prostacyclin synthesis and as modulation by platelet-derived growth factor, 78, 7134

Halpern, 1960, Raynaud's disease, Raynaud's phenomenon and serotonin, Angiology, 11, 151, 10.1177/000331976001100301

Acharya, 1983, Platelet products and vascular PGI2 production, Prostaglandins Leukotrienes Med, 10, 73, 10.1016/S0262-1746(83)80022-5

Jones, 1979, Platelet function in arterial vascular disease, Thromb Haemost, 42, 147

Nichols, 1982, Fibrinopeptide A, platelet factor 4 and β-thromboglobulin levels in coronary artery disease, Blood, 60, 650, 10.1182/blood.V60.3.650.650

Hirsh, 1981, Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease, N Engl J Med, 304, 685, 10.1056/NEJM198103193041201

Kahaleh, 1982, Elevated levels of circulating platelet aggregates and beta thromboglobulin in scleroderma, Ann Intern Med, 96, 610, 10.7326/0003-4819-96-5-610

Rodeheffer, 1983, Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon, N Engl J Med, 308, 880, 10.1056/NEJM198304143081507

Smith, 1982, Controlled trial of nifedipine in the treatment of Raynaud's phenomenon, Lancet, II, 1299, 10.1016/S0140-6736(82)91508-2

Han, 1983, Effect of the calcium-entry blocking agent nifedipine on activation of human platelets and comparison with verapimil, Thromb Haemost, 50, 513, 10.1055/s-0038-1665243

Ettinger, 1984, Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon, Am J Med, 77, 451, 10.1016/0002-9343(84)90101-3

Levine, 1981, The importance of blood collection methods for assessment of platelet activation, Thromb Res, 24, 433, 10.1016/0049-3848(81)90077-3

Ludlam, 1976, Studies on the liberation of β-thromboglobulin from human platelets in vitro, Br J Haematol, 33, 239, 10.1111/j.1365-2141.1976.tb03535.x

Fitzgerald, 1984, Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation, N Engl J Med, 310, 1065, 10.1056/NEJM198404263101701

Kaplan, 1981, Plasma levels of β-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo, Blood, 57, 199, 10.1182/blood.V57.2.199.199

Dawes, 1978, The release, distribution and clearance of human β-thromboglobulin and platelet factor 4, Thromb Res, 12, 851, 10.1016/0049-3848(78)90279-7

Ludlam, 1975, The release of a human platelet specific protein measured by a radioimmunoassay, Thromb Res, 6, 543, 10.1016/0049-3848(75)90066-3

Rodbard, 1969, Rapid calculation of radioimmunoassay results, J Lab Clin Med, 74, 770

Brecher, 1964, Estimation of the number of platelets by phase microscopy, 128

Snedecor, 1967

Hutton, 1984, Assessment of platelet function in patients with Raynaud's syndrome, J Clin Pathol, 37, 182, 10.1136/jcp.37.2.182

Files, 1981, Studies of human platelet α-granule release in vitro, Blood, 58, 607, 10.1182/blood.V58.3.607.607

Zahavi, 1980, Plasma exchange and platelet function In Raynaud's phenomenon, Thromb Res, 19, 85, 10.1016/0049-3848(80)90406-5

Dorsch, 1980, Elevated β-thromboglobulin levels in systemic lupus erythematosus, Thromb Res, 20, 617, 10.1016/0049-3848(80)90150-4

Zahavi, 1980, β-thromboglobulin—a specific marker of In vivo platelet release reaction, Thromb Haemost, 44, 23, 10.1055/s-0038-1650073

Ardlie, 1982, Calcium ions, drug action and platelet function, Pharmacol Ther, 18, 249, 10.1016/0163-7258(82)90069-9

Packham, 1983, Platelet function inhibitors, Thromb Haemost, 50, 610, 10.1055/s-0038-1665267

Dale, 1983, The effects of nifedipine, a calcium antagonist, on platelet function, Am Heart J, 105, 103, 10.1016/0002-8703(83)90285-5

Johnsson, 1981, Effects by nifedipine (Adalat) on platelet function in vitro and in vivo, Thromb Res, 21, 523, 10.1016/0049-3848(81)90155-9

Cohn, 1982, Calcium ions, drug action and platelet function, Circulation, 65, 1

Vanhoute, 1982, Calcium-entry blockers and vascular smooth muscle, Circulation, 65, 11

Moncada, 1979, Arachidonic acid metabolites and the interactions between platelets and blood vessel walls, N Engl J Med, 300, 1142, 10.1056/NEJM197905173002006

Rutherford, 1976, Platelet factors stimulate fibroblasts and smooth muscle cells in quiescent plasma serum to proliferate, J Cell Biol, 69, 196, 10.1083/jcb.69.1.196

King, 1984, Characterization and partial purification of an endothelial cell growth factor from human platelets, J Clin Invest, 73, 392, 10.1172/JCI111224

Hope, 1979, Human β-thromboglobulin inhibits PGI2 production and binds to a specific site in bovine aortic endothelial cells, Nature, 282, 210, 10.1038/282210a0

Norton, 1970, Vascular disease in progressive systemic sclerosis, Ann Intern Med, 73, 317, 10.7326/0003-4819-73-2-317

Randall, 1983, Selective inhibition of thromboxane synthesis with dazoxiben in animals and man, Thromb Res, 81, 10.1016/0049-3848(83)90362-6

Dale, 1983, The effect of a thromboxane synthetase inhibitor, dazoxiben and acetylsalicylic acid on platelet function and prostaglandin metabolism, Thromb Haemost, 50, 703, 10.1055/s-0038-1665291

Vermylen, 1981, Thromboxane synthetase inhibition as antithrombotic therapy, Lancet, I, 1073, 10.1016/S0140-6736(81)92241-8

Luderer, 1984, Dazoxiben, a thromboxane synthetase inhibitor, in Raynaud's phenomenon, Clin Pharmacol Ther, 36, 105, 10.1038/clpt.1984.147

Heptinstall, 1980, Effects of a selective inhibitor of thromboxane synthetase on human blood platelet behavior, Thromb Res, 20, 219, 10.1016/0049-3848(80)90387-4